CN102716347B - Tibetan medicine for treating hypertension and preparation method thereof - Google Patents
Tibetan medicine for treating hypertension and preparation method thereof Download PDFInfo
- Publication number
- CN102716347B CN102716347B CN2012102193404A CN201210219340A CN102716347B CN 102716347 B CN102716347 B CN 102716347B CN 2012102193404 A CN2012102193404 A CN 2012102193404A CN 201210219340 A CN201210219340 A CN 201210219340A CN 102716347 B CN102716347 B CN 102716347B
- Authority
- CN
- China
- Prior art keywords
- radix
- herba
- tibetan medicine
- active component
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 89
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims description 18
- 241000218176 Corydalis Species 0.000 claims abstract description 20
- 239000002552 dosage form Substances 0.000 claims abstract description 4
- 239000006187 pill Substances 0.000 claims description 19
- 239000009609 fructus phyllanthi Substances 0.000 claims description 18
- 240000001312 Pecteilis susannae Species 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000469 ethanolic extract Substances 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 238000007560 sedimentation technique Methods 0.000 claims description 2
- 230000036772 blood pressure Effects 0.000 abstract description 36
- 206010019233 Headaches Diseases 0.000 abstract description 7
- 208000002173 dizziness Diseases 0.000 abstract description 7
- 231100000869 headache Toxicity 0.000 abstract description 7
- 210000005036 nerve Anatomy 0.000 abstract description 4
- 206010033557 Palpitations Diseases 0.000 abstract description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 3
- 235000013399 edible fruits Nutrition 0.000 abstract description 3
- 230000006870 function Effects 0.000 abstract description 3
- 206010022437 insomnia Diseases 0.000 abstract description 3
- 244000119298 Emblica officinalis Species 0.000 abstract description 2
- 235000015489 Emblica officinalis Nutrition 0.000 abstract description 2
- 241000305491 Gastrodia elata Species 0.000 abstract description 2
- 241000572480 Rubia wallichiana Species 0.000 abstract description 2
- 208000009205 Tinnitus Diseases 0.000 abstract description 2
- 241001643425 Tinospora sinensis Species 0.000 abstract description 2
- 229940126701 oral medication Drugs 0.000 abstract description 2
- 231100000886 tinnitus Toxicity 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 3
- 241000619366 Caragana sinica Species 0.000 abstract 1
- 241000628997 Flos Species 0.000 abstract 1
- 241000407052 Hymenidium hookeri Species 0.000 abstract 1
- 241001495448 Impatiens <genus> Species 0.000 abstract 1
- 235000002598 Inula helenium Nutrition 0.000 abstract 1
- 244000116484 Inula helenium Species 0.000 abstract 1
- 241000635276 Lagotis glauca Species 0.000 abstract 1
- 229920001800 Shellac Polymers 0.000 abstract 1
- 241000208041 Veronica Species 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 229930190166 impatien Natural products 0.000 abstract 1
- 231100000862 numbness Toxicity 0.000 abstract 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 abstract 1
- 229940113147 shellac Drugs 0.000 abstract 1
- 235000013874 shellac Nutrition 0.000 abstract 1
- 239000004208 shellac Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 42
- 241000700159 Rattus Species 0.000 description 27
- 210000004369 blood Anatomy 0.000 description 26
- 239000008280 blood Substances 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 230000001737 promoting effect Effects 0.000 description 15
- 230000035487 diastolic blood pressure Effects 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 239000013641 positive control Substances 0.000 description 13
- 206010004542 Bezoar Diseases 0.000 description 12
- 239000000796 flavoring agent Substances 0.000 description 12
- 235000019634 flavors Nutrition 0.000 description 12
- 230000035488 systolic blood pressure Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 10
- 230000017531 blood circulation Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000001631 hypertensive effect Effects 0.000 description 10
- 230000036407 pain Effects 0.000 description 10
- 208000011580 syndromic disease Diseases 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 7
- 230000004087 circulation Effects 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000036461 convulsion Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010001497 Agitation Diseases 0.000 description 3
- 240000004460 Tanacetum coccineum Species 0.000 description 3
- 208000019790 abdominal distention Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 2
- 239000003390 Chinese drug Substances 0.000 description 2
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 2
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 206010029216 Nervousness Diseases 0.000 description 2
- 240000000103 Potentilla erecta Species 0.000 description 2
- 235000016551 Potentilla erecta Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- -1 dry below 60 °C Substances 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000008384 feverfew Nutrition 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 244000296912 Ageratum conyzoides Species 0.000 description 1
- 235000004405 Ageratum conyzoides Nutrition 0.000 description 1
- 241000208223 Anacardiaceae Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241001533085 Aquilaria sinensis Species 0.000 description 1
- 206010003084 Areflexia Diseases 0.000 description 1
- 206010003175 Arterial spasm Diseases 0.000 description 1
- 208000006770 Ascorbic Acid Deficiency Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000007333 Brain Concussion Diseases 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 235000016535 Capraria biflora Nutrition 0.000 description 1
- 241000792739 Caragana changduensis Species 0.000 description 1
- 241000785897 Caragana jubata Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 235000018912 Chrysanthemum tatsienense Nutrition 0.000 description 1
- 241001139841 Chrysanthemum tatsienense Species 0.000 description 1
- 206010009346 Clonus Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 208000016998 Conn syndrome Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000221017 Euphorbiaceae Species 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241001516928 Kerria lacca Species 0.000 description 1
- 241000382298 Lagotis Species 0.000 description 1
- 241000382297 Lagotis brachystachya Species 0.000 description 1
- 241000600550 Lagotis brevituba Species 0.000 description 1
- 241000984129 Lagotis integra Species 0.000 description 1
- 241001582888 Lobus Species 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 241000607292 Maguireothamnus speciosus Species 0.000 description 1
- 241000219071 Malvaceae Species 0.000 description 1
- 241000218164 Menispermaceae Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241001050834 Onosma hookerii Species 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 241000244271 Pleurospermum Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000410468 Pterostyrax Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 241000130953 Rhodiola tibetica Species 0.000 description 1
- 244000272264 Saussurea lappa Species 0.000 description 1
- 235000006784 Saussurea lappa Nutrition 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 201000004239 Secondary hypertension Diseases 0.000 description 1
- 241001563853 Sphallerocarpus gracilis Species 0.000 description 1
- 244000218979 Spondias axillaris Species 0.000 description 1
- 235000014116 Spondias axillaris Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 240000003428 Tinospora crispa Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- ROVGZAWFACYCSP-MQBLHHJJSA-N [2-methyl-4-oxo-3-[(2z)-penta-2,4-dienyl]cyclopent-2-en-1-yl] (1r,3r)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OC1C(C)=C(C\C=C/C=C)C(=O)C1 ROVGZAWFACYCSP-MQBLHHJJSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229960000796 barbital sodium Drugs 0.000 description 1
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000138993 panchioli Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 208000013846 primary aldosteronism Diseases 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000035485 pulse pressure Effects 0.000 description 1
- 229940015367 pyrethrum Drugs 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 208000010540 rapid respiration Diseases 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a tibetan medicine for treating hypertension, which is composed of active ingredients or active ingredients and pharmaceutically acceptable additives, wherein the active ingredients are prepared from agilawood, lagotisglauca, corydalis pygmaea, radix onosmatis, tinospora sinensis merr, elecampane, pleurospermum hookeri, flos pyrethri tatsienensis, caragana sinica, shellac,rubia wallichiana decne, gastrodia elata, fructus choerospondiatis, fruit of emblic leafflower and corydalis impatiens according to a weight ratio. The tibetan medicine can be prepared to any common oral medication dosage form. The tibetan medicine disclosed by the invention has the functions of soothing the nerves, quieting the heart and decreasing the blood pressure. The tibetan medicine is suitable for headache, dizziness, limb numbness, palpitation, dismay, tinnitus, insomnia and hypertension.
Description
Technical field
The present invention relates to a kind of Tibetan medicine for the treatment of hypertension and preparation method thereof, belong to the Tibetan medicine field.
Background technology
Hypertension is a kind of common, the clinical syndrome that increases based on systemic arterial pressure.The hypertensive cause of disease is not bright, may be relevant with age, occupation, environment, Inheritance, salinity and body weight factor, it is generally acknowledged that the higher nervous center functional disorder occupies an leading position in morbidity, and body fluid endocrine factors and kidney etc. have also participated in pathogenic process.Prolonged and repeated hypertonicity and direct stimulation make the cerebral cortex dysfunction, lose the normal regulating effect to vasomotor centre under the cerebral cortex, formed with the vasoconstrictor nerve dominant focus of excitation of getting excited, caused the tiny arteriospasm of whole body, peripheral vascular resistance increases, increased blood pressure.
Hypertension is the commonly encountered diseases of serious threat health of people, is the important risk factor of coronary heart disease and cerebrovascular.Along with expanding economy, the change of people life style and the quickening of work rhythm, hypertensive prevalence is ascendant trend year by year.Chinese residents nutrition and investigation of health conditions result show, China adult hypertension prevalence is 18.8%, estimate that there is hyperpietic 1.6 hundred million in the present whole nation, become the important diseases of serious threat China people ' s health, in a single day apoplexy or myocardial infarction take place in the hyperpietic, will directly threaten patient's life, or leave over lifelong deformity, bring white elephant for patient and family members.
Evil does not greatly have better solution at present as yet although this is critically ill, though Western medicine can make blood pressure control rapidly, undulatory property is big, often needs several depressor drug combinations, and exists certain toxic and side effects; Chinese medicine, the hypertensive medicine of collaborative treatment of Chinese and western medicines are also a lot, and have obtained certain curative effect, but still have some patients to depressor unsatisfactory curative effect commonly used, or can not use because of its side effect; Advantages such as and Tibetan medicine treatment hypertension then has effect lastingly, and side effect is little.
Therefore, there is tight demand in people's Tibetan medicinal preparation that curative effect is better treated hypertension.Up to now, also do not find the report of any relevant Tibetan medicine compositions of the present invention.The inventor is through research repeatedly, and the checking repeatedly by animal and clinical trial, has found the Tibetan medicine oral drugs that the treatment of better curative effect hypertension is arranged finally, thereby has finished the present invention.
Summary of the invention
The object of the invention just provides a kind of Tibetan medicine of more effectively treating hypertension.
Another object of the present invention has provided the preparation method of this Tibetan medicine.
The present invention is a kind of Tibetan medicine, formed or be made up of active component and acceptable accessories by active component, wherein said active component is to be made by following bulk drugs: Lignum Aquilariae Resinatum, Radix Pecteilis susannae, Herba Corydalis, Radix onosmatis, Herba Lycopodii, the Radix Aucklandiae, Herba pleurospermi thomsonii, DAJIANJU, ZANGJINJIER, Lacca, ZANGQIANCAO, Rhizoma Gastrodiae, Fructus Choerospondiatis, Fructus Phyllanthi, Corydalisimpatiens(Pall.)Fisch.
It has selected Lignum Aquilariae Resinatum, Radix Pecteilis susannae, Herba Corydalis, Radix onosmatis, Herba Lycopodii, the Radix Aucklandiae, Herba pleurospermi thomsonii, DAJIANJU, ZANGJINJIER, Lacca, ZANGQIANCAO, Rhizoma Gastrodiae, Fructus Choerospondiatis, Fructus Phyllanthi, Corydalisimpatiens(Pall.)Fisch to make up as raw material, and wherein (1) Lignum Aquilariae Resinatum is the timber that thymelaeceae plant Lignum Aquilariae Resinatum Aquilariasinensis (Lour.) Gilg contains resin.Nature and flavor suffering, hardship, tepor; Return spleen, stomach, kidney channel.Have promoting the circulation of QI to relieve pain, warming middle-JIAO to arrest vomiting, the function of helping inspiration to relieve asthma.Be used for the vexed pain of breast abdominal distention, gastrofrigid vomiting singultus, the QI rising in reverse order of suffering from a deficiency of the kidney dyspnea with rapid respiration.Have inhibition, antibiotic, pain relieving, calmness, Zhichuan, blood pressure lowering, arrhythmia and pharmacological action such as resist myocardial ischemia.(2) Radix Pecteilis susannae is the dry herb of goatweed Lagotis brachystachya Maxim Lagotis brevituba Maxim. or Herba Lagotis integrae L.integra W.Smith..Nature and flavor hardship, sweet, cold; Has heat-clearing and toxic substances removing, the effect of promoting the circulation of blood regulating menstruation; Control the whole body heating, nephritis, pneumonopathy, hypertension, atherosclerosis, menoxenia, synthesis toxic poisoning and " heat in the heart " disease; Have protect the liver, the effect of analgesia, antiinflammatory.(3) Herba Corydalis is the dry herb of bloodroot Herba Corydalis Corydalis hendersonii Hemsl. (C.nepaiesis kitamura) and flat handle Herba corydalis racemosae C.mucionifera Maxim..The nature and flavor hardship, cold; Effect with heat clearing and inflammation relieving; Be used for the high mountain plethora, ulcer pain, vasculitis, enteritis.(4) Radix onosmatis is the root of comfrey long flower Yunnan Radix Arnebiae (Radix Lithospermi) Onosma hookeri Clarke.var.longiforum Duthie and thin flower Yunnan Radix Arnebiae (Radix Lithospermi) Onoasma hookeri C.B.Clarke.Nature and flavor are sweet, cold; Have clearing away heat and cooling blood, support the effect of lung; Be used for pneumonia, tuberculous cavity, high mountain plethora.(5) Herba Lycopodii is the dry stem of menispermaceae plant lobus cardiacus Herba Lycopodii Tinospora cordifolia (wulld) Miers or Herba Lycopodii T.sinensis (Lour.) Merr..Nature and flavor hardship, puckery, cold; Return Liver Channel.Have clearing heat and moistening lung, the function of disorder due to the blending pathology.Be used for liver-heat, visceral heat, pneumonopathy, rheumatic arthritis, ageing diseases.Have anti-diabetic, tuberculosis, pharmacological action such as antibiotic.(6) Radix Aucklandiae is the dry root of feverfew Radix Aucklandiae Aucklandia lappa Decne..Acrid in the mouth, hardship, digestion back bitter in the mouth, warm in nature, effect is moistened and is wet; Return spleen, stomach, large intestine, three warmers, gallbladder meridian; Have promoting the circulation of QI to relieve pain, strengthening the spleen to promote digestion, broken painful abdominal mass knot, the effect of granulation promoting; Be used for the breast side of body, abdominal distention, " dragon " disease, disorders of blood, diphtheria, pneumonopathy, " Baconic " is poly-to stagnate, diarrhea of heat type, the open sore part is not held back etc.; Have blood pressure lowering, suppress smooth muscle, antibiotic pharmacological action.(7) Herba pleurospermi thomsonii is samphire Herba pleurospermi thomsonii Pleurospermum tibetanicum(Turcz.) Schischk. or Sphallerocarpus gracilis Sphallerocarpus gracillis(Bess) dry root of K.-Pol., nature and flavor suffering, puckery, warm, the diseases caused by retention of the body fluid of harnessing the Yellow River, nephropathy, lumbago, swell and ache Baconic's disease, wooden brucellosis, sick and the flu of dragon, gastropathy, dyspepsia, abdomen is cold.(8) DAJIANJU is the dry inflorescence of feverfew west szechwan pyrethrum Pyrethrum tatsienense (Bur.et Franch.) Ling.The nature and flavor hardship, cold; Has dissipating blood stasis, pain relieving, the effect of holding back " yellow fluid "; Be used for grasserie, cerebral concussion, pestilence, temple pain and traumatic injury and warm skin infection.(9) ZANGJINJIER is leguminous plant Cortes seu Caulis Caraganae jubatae Caragana jubata(pall.) the woody part heartwood of Poir. and Changdu caragana Caragana changduensis fiauf.Nature and flavor are puckery, cold; Return the liver,spleen,kidney warp; Have effects such as blood circulation promoting and blood stasis dispelling, blood pressure lowering, scattered inflammatory swelling, be used for the treatment of hypertension, plethora, menoxenia, external curing traumatic injury etc.(10) Lacca is that the female body of Lacciferidae animal lac insect Laccifer lacca Kerr. parasitizes the pulse family wingceltis and belongs on the trunk that Dalbergia L.f. and Sterculiaceae rope of plaited plants Pterostyrax Eriolaenea DC. etc. are main various plants secreted colloid.Nature and flavor are sweet, salty, and are flat; Has sterilization, hemostasis, the effect of blood circulation promoting and blood stasis dispelling; Be used for blood consumptive disease heat, the toxic swelling malignant boil, blood stasis is not changed.(11) ZANGQIANCAO is Maguireothamnus speciosus light stem Radix Rubiae Rubia wallichiana Decne. and Tibet Radix Rubiae R.tibetica Hook.f. and the dry root and rhizome that belongs to several plants together.Nature and flavor hardship, suffering; Effect with clearing away heat and cooling blood; Be used for disorders of blood, diffusion is got mildewed in warm conditions, lung kidney-heat heresy, intestine and small intestine heat.(12) Rhizoma Gastrodiae is the dry tuber of orchid Rhizoma Gastrodiae Gastrodia elata Bl..Nature and flavor are sweet, and are flat; Return Liver Channel.Effect with suppressing the hyperactive liver to relieve the wind syndrome relieving convulsion.It is dizzy to be used for headache, numb limbs and tense tendons, infantile convulsion, epilepsy clonus, tetanus.Have calmness, convulsion, blood pressure lowering, antiinflammatory, resisting oxygen lack, increase the myocardial nutrition blood flow, improve the cardiac muscle circulation, increase myocardial oxygen delivery, myocardial ischemia is had pharmacological actions such as protective effect.(13) Fructus Choerospondiatis is the dry mature fruit of Anacardiaceae plant Fructus Choerospondiatis Choerospondias axillaris (Roxb.) Burtt et Hill.Nature and flavor are sweet, sour, and are flat.Have promoting flow of QI and blood, nourish heart, the effect of calming the nerves.Be used for qi depression to blood stasis, the thoracic obstruction is had a pain, shortness of breath and palpitation, irritability.Fructus Choerospondiatis total flavones (TFC) has the expansion effect of guarantor and antiarrhythmic effect to animal anoxia enduring and acute myocardial ischemia, and platelet aggregation is had the obvious suppression effect, can make the blood flow pick up speed, improves blood circulation and microcirculation.(14) Fructus Phyllanthi is the fruit of Euphorbiaceae phyllanthus plant Fructus Phyllanthi Phyllanthus emblica L..Sweet in the mouth, acid, puckery, cool in nature; Has clearing away heat and cooling blood, promoting digestion and invigorating the stomach, the effect of promoting the production of body fluid to quench thirst; Cure mainly the heat in blood blood stasis, dyspepsia, abdominal distention, cough, laryngalgia, xerostomia and vitamin C deficiency disease; In Tibetan medicine, Fructus Phyllanthi cures mainly Baconic's disease, red bar disease, disorders of blood, hypertension etc.; In recent years result of study shows, Fructus Phyllanthi has antiinflammatory, antioxidation, and defying age such as protects the liver at effect.(15) Corydalisimpatiens(Pall.)Fisch is bloodroot Corydalisimpatiens(Pall.)Fisch Corydalisimpatiens(Pall.) herb of Fisch.Bitter in the mouth, digestion back bitter in the mouth, cool in nature; Has promoting blood circulation to remove blood stasis, promoting the circulation of QI to relieve pain, the effect of heat-clearing and toxic substances removing; Be used for gallbladder-heat, epidemic disease flu, gastric abscess, hepatitis, cholecystitis, lumbago and skelalgia, carbuncle, scabies, venom, knife injury etc.Can reduce the blood lipid level of experimental hyperlipidemia rat, and can reduce blood viscosity, prevent platelet aggregation, improve pharmacological actions such as blood flow.
Dragon is contained burning hot, and blood is bad to drive in the wrong direction, thereby hypertension, headache, dizziness, numb limbs and tense tendons, cardiopalmus, clinical symptoms such as nervous occur, and treatment should be to hold back bad blood, the imperial blood pressure lowering of breath.Lignum Aquilariae Resinatum, Fructus Choerospondiatis have the effect of promoting blood circulation to remove obstruction in the collateral and tranquilizing by nourishing the heart in the side; " three is red " medicines such as Lacca, Radix onosmatis, ZANGQIANCAO are to regulate various hemopathic choice drugs; The Fructus Phyllanthis, ZANGJINJIER, Corydalisimpatiens(Pall.)Fisch, Radix Pecteilis susannae, DAJIANJU, Herba pleurospermi thomsonii, Herba Corydalis etc. that reduce phlegm, hold back bad blood, blood circulation promoting and blood stasis dispelling with clearing away heat and cooling blood, dehumidifying can play clearing away heat and cooling blood, nourishing the liver, the blood pressure lowering of invigorating blood circulation, dehumidifying are reduced phlegm, the effect of promoting the production of body fluid to quench thirst, and the Rhizoma Gastrodiae that is equipped with the suppressing the hyperactive liver to relieve the wind syndrome relieving convulsion again strengthens drug effect; Regulate the flow of vital energy with the Radix Aucklandiae, Herba Lycopodii and to fall dragon, relieving distension by promoting circulation of QI is separated pyretic toxicity, pain relieving.Make each efficacy of drugs produce synergism these drug regimens, thereby can effectively treat hypertension.
The consumption of Tibetan medicine component of the present invention is also groped to sum up to draw through the inventor in a large number, and each crude drug consumption is for all having better curative effect in following concrete weight proportion scope:
Lignum Aquilariae Resinatum 20～100g, Radix Pecteilis susannae 10～80g, Herba Corydalis 10～80g, Radix onosmatis 10～60g, Herba Lycopodii 10～60g, the Radix Aucklandiae 10～60g, Herba pleurospermi thomsonii 10～60g, DAJIANJU 10～80g, ZANGJINJIER 20～100g, Lacca 10～60g, ZANGQIANCAO 10～80g, Rhizoma Gastrodiae 10～60g, Fructus Choerospondiatis 10～60g, Fructus Phyllanthi 20～100g, Corydalisimpatiens(Pall.)Fisch 10～60g.
Be preferably: Lignum Aquilariae Resinatum 48g, Radix Pecteilis susannae 36g, Herba Corydalis 36g, Radix onosmatis 28g, Herba Lycopodii 28g, Radix Aucklandiae 28g, Herba pleurospermi thomsonii 28g, DAJIANJU 36g, ZANGJINJIER 42g, Lacca 28g, ZANGQIANCAO 36g, Rhizoma Gastrodiae 28g, Fructus Choerospondiatis 28g, Fructus Phyllanthi 42g, Corydalisimpatiens(Pall.)Fisch 28g.
The preparation of Tibetan medicine active component of the present invention can be the crude drug convection drying of above-mentioned consumption to be pulverized make; Also the crude drug of above-mentioned consumption can be adopted the conventional method of Chinese medicine preparation such as decoction and alcohol sedimentation technique or ethanol extract from water precipitation (referring to Cao Chunlin chief editor's " pharmaceutics of Chinese drugs " the 73rd～74 page, Science and Technology of Shanghai publishing house publishes in November, 1986) to make.
The active component of Tibetan medicine of the present invention can add various conventional adjuvant required when preparing different dosage form, as disintegrating agent, lubricant, binding agent etc. with the method for Chinese medicinal of routine (referring to Cao Chunlin chief editor's " pharmaceutics of Chinese drugs ", Science and Technology of Shanghai publishing house publishes in November, 1986) be prepared into any peroral dosage form commonly used, as powder, pill, capsule, granule, tablet etc.
Tibetan medicine of the present invention has calms the nerves, mind calming, the effect of blood pressure lowering.Be applicable to headache, dizziness, numb limbs and tense tendons, cardiopalmus, nervous, tinnitus, insomnia, vascular hypertension.
The usage and dosage of Tibetan medicine of the present invention is: oral; A 1～1.5g, 2～3 times on the one.
[specific embodiment]
Come further to set forth the preparation method of Tibetan medicine of the present invention by the following examples.
The powder preparation of [embodiment 1] Tibetan medicine of the present invention:
Take by weighing Lignum Aquilariae Resinatum 48g, Radix Pecteilis susannae 36g, Herba Corydalis 36g, Radix onosmatis 28g, Herba Lycopodii 28g, Radix Aucklandiae 28g, Herba pleurospermi thomsonii 28g, DAJIANJU 36g, ZANGJINJIER 42g, Lacca 28g, ZANGQIANCAO 36g, Rhizoma Gastrodiae 28g, Fructus Choerospondiatis 28g, Fructus Phyllanthi 42g, Corydalisimpatiens(Pall.)Fisch 28g, be ground into fine powder after the mixing jointly, mixing, packing namely gets powder.
The pill preparation of [embodiment 2] Tibetan medicine of the present invention:
Take by weighing Lignum Aquilariae Resinatum 58g, Radix Pecteilis susannae 40g, Herba Corydalis 40g, Radix onosmatis 24g, Herba Lycopodii 24g, Radix Aucklandiae 24g, Herba pleurospermi thomsonii 24g, DAJIANJU 40g, ZANGJINJIER 50g, Lacca 24g, ZANGQIANCAO 40g, Rhizoma Gastrodiae 24g, Fructus Choerospondiatis 24g, Fructus Phyllanthi 40g, Corydalisimpatiens(Pall.)Fisch 24g, be ground into fine powder after the mixing jointly, mixing, use water pill, dry below 60 ℃, polishing, packing namely gets pill.
The granule preparation of [embodiment 3] Tibetan medicine of the present invention:
Take by weighing Lignum Aquilariae Resinatum 38g, Radix Pecteilis susannae 30g, Herba Corydalis 50g, Radix onosmatis 20g, Herba Lycopodii 28g, Radix Aucklandiae 20g, Herba pleurospermi thomsonii 28g, DAJIANJU 40g, ZANGJINJIER 65g, Lacca 20g, ZANGQIANCAO 48g, Rhizoma Gastrodiae 20g, Fructus Choerospondiatis 20g, Fructus Phyllanthi 53g, Corydalisimpatiens(Pall.)Fisch 20g, be ground into fine powder after the mixing jointly, mixing, add adjuvant and make granule, dry below 60 ℃, granulate, packing namely gets granule.
The capsule preparation of [embodiment 4] Tibetan medicine of the present invention:
Take by weighing Lignum Aquilariae Resinatum 60g, Radix Pecteilis susannae 35g, Herba Corydalis 25g, Radix onosmatis 35g, Herba Lycopodii 20g, Radix Aucklandiae 20g, Herba pleurospermi thomsonii 20g, DAJIANJU 45g, ZANGJINJIER 55g, Lacca 25g, ZANGQIANCAO 25g, Rhizoma Gastrodiae 50g, Fructus Choerospondiatis 30g, Fructus Phyllanthi 20g, Corydalisimpatiens(Pall.)Fisch 35g, be ground into fine powder after the mixing jointly, mixing, the gelatine capsule of packing into namely gets capsule.
The preparation tablets of [embodiment 5] Tibetan medicine of the present invention:
Take by weighing Lignum Aquilariae Resinatum 55g, Radix Pecteilis susannae 45g, Herba Corydalis 30g, Radix onosmatis 35g, Herba Lycopodii 35g, Radix Aucklandiae 35g, Herba pleurospermi thomsonii 35g, DAJIANJU 45g, ZANGJINJIER 45g, Lacca 20g, ZANGQIANCAO 30g, Rhizoma Gastrodiae 20g, Fructus Choerospondiatis 20g, Fructus Phyllanthi 30g, Corydalisimpatiens(Pall.)Fisch 20g, be ground into fine powder after the mixing jointly, mixing, add adjuvant and make granule, dry below 60 ℃, granulate, tabletting namely gets tablet.
Below further sets forth the beneficial effect of Tibetan medicine of the present invention by testing example, these are tested the routine pharmacodynamics test of Tibetan medicine embodiment 1 of the present invention and the clinical observation on the therapeutic effect of having comprised and test.
The influence of [test example 1] 1 pair of rat blood pressure of Tibetan medicine embodiment of the present invention:
Test material: anthology invention Tibetan medicine embodiment 1; Bezoar pill for lowering blood pressure is produced by the Beijing Tongrentang Technology Development Co.ltd. Pharmaceutical Factory, lot number 20091013; Common rat, Hypertensive Rats are provided by Qinghai Province's Experimental Animal Center.
Experimental technique: 1, to the influence of common rat blood pressure: get 40 of male common rats; body weight 210～260g; be divided into 4 groups at random, normally raise after 2 days and experimentize, establish model control group, positive controls (Bezoar pill for lowering blood pressure 0.32g/Kg) and Tibetan medicine embodiment 1(0.75g/kg of the present invention; 3.00g/kg) low, high dose group; gastric infusion, 20ml/Kg, be administered once every day; continuous 5d, model control group is given the equivalent normal saline.1h begins test and respectively organizes rat blood pressure after the last administration.With 20% urethane intraperitoneal injection of anesthesia rat, separate carotid artery, carry out arterial cannulation, connect the twice physiograph.
2, to the effect of hypertensive rat blood pressure: experimental technique and use instrument condition with 1.
Experimental result: 1, the influence of 1 pair of common rat blood pressure of Tibetan medicine embodiment of the present invention sees Table 1.
The influence of 1 pair of common rat blood pressure of table 1 Tibetan medicine embodiment of the present invention (x ± s, n=10)
Group number of animals dosage (g/kg) systolic pressure (KPa)
Diastolic pressure (KPa) heart rate (inferior/min)
Model control group 10 15.2 ± 0.64 12.4 ± 0.47 420.6 ± 19.35
Positive controls 10 0.32 11.4 ± 2.78
*6.9 ± 2.57
* *399 ± 71.47
Low dose group 10 0.75 11.1 ± 2.52
* *6.8 ± 2.13
* *415 ± 39.18
High dose group 10 3.00 11.2 ± 2.54
*6.7 ± 2.78
*397 ± 21.57
Illustrate: with the model matched group relatively:
*P＜0.01;
* *P＜0.001.
As seen from Table 1: the positive controls Bezoar pill for lowering blood pressure compares with model control group common rat diastolic pressure and systolic pressure influence, and blood pressure drops is (P＜0.01) very obviously; The reduction effect of 1 pair of common rat diastolic pressure of Tibetan medicine embodiment of the present invention and systolic pressure is compared with model control group, and same highly significant (P＜0.01) illustrates that Tibetan medicine embodiment 1 of the present invention has the hypotensive effect of highly significant.
2, the effect of 1 pair of hypertensive rat blood pressure of Tibetan medicine embodiment of the present invention sees Table 2.
The effect of 1 pair of hypertensive rat blood pressure of table 2 Tibetan medicine embodiment of the present invention (x ± s, n=10)
Group number of animals dosage (g/kg) systolic pressure (KPa)
Diastolic pressure (KPa) heart rate (inferior/min)
Model control group 10 12.8 ± 1.29 17.4 ± 0.92 398.5 ± 45.85
Positive controls 10 0.32 6.9 ± 0.78
* *10.8 ± 14.7
* *397.8 ± 49.67
Low dose group 10 0.75 11.8 ± 1.09 15.1 ± 1.82
*407.4 ± 43.28
High dose group 10 3.00 6.7 ± 1.44
* *10.1 ± 1.58
*391.3 ± 43.37
Illustrate: with the model matched group relatively:
*P＜0.01;
* *P＜0.001.
As seen from Table 2: with model control group relatively, the positive controls Bezoar pill for lowering blood pressure can make the blood pressure of Hypertensive Rats significantly descend (P＜0.001); Tibetan medicine embodiment 1 of the present invention can make hypertensive rat blood pressure very obviously descend (P＜0.001), and therefore the treatment to the hypertensive patient has certain clinical value.
On the other hand, when bringing high blood pressure down, alteration in heart rate is more steady, simultaneously electrocardio is not had obvious influence.
The influence of [test example 2] 1 pair of rat fat of Tibetan medicine embodiment of the present invention:
Test material: anthology invention Tibetan medicine embodiment 1; Bezoar pill for lowering blood pressure is produced by the Beijing Tongrentang Technology Development Co.ltd. Pharmaceutical Factory, lot number 20091013; Common rat is provided by Qinghai Province's Experimental Animal Center.
Experimental technique: 1, to the influence of common rat cholesterol level: get 30 of male common rats; body weight 210～260g; be divided into 3 groups at random; if model control group, positive controls (Bezoar pill for lowering blood pressure 0.32g/Kg) and experiment medicine group (Tibetan medicine embodiment 1 of the present invention, dosage 3.00g/kg), gastric infusion; 20ml/Kg; be administered once every day, continuous 6d, and model control group is given the equivalent normal saline.6d evening, water was can't help in fasting, and carotid artery was got blood and tested by enzyme linked immunosorbent assay next day.
2, to the influence of common rat content of triglyceride: experimental technique with to the serum triglycerides content assaying method with 1.
Experimental result: 1, the influence of 1 pair of common rat blood serum cholesterol level of Tibetan medicine embodiment of the present invention sees Table 3.
The influence of 1 pair of common rat blood serum cholesterol level of table 3 Tibetan medicine embodiment of the present invention (x ± s, n=10)
Group number of animals dosage (g/kg) cholesterol level (mmol/L)
Model control group 10 5.46 ± 0.73
Positive controls 10 0.32 4.89 ± 0.67
*
Experiment medicine group 10 3.00 4.02 ± 0.54
*
Illustrate: with the model matched group relatively:
*P〉0.05;
*P＜0.01.
As seen from Table 3: though the positive controls Bezoar pill for lowering blood pressure descends serum cholesterol content, with model control group not statistically significant (P〉0.05) relatively; Tibetan medicine embodiment of the present invention 1 and model control group relatively can make rat blood serum cholesterol level significantly descend (P＜0.01).
2, the influence of 1 pair of common rat blood serum content of triglyceride of Tibetan medicine embodiment of the present invention sees Table 4.
The influence of 1 pair of common rat blood serum content of triglyceride of table 4 Tibetan medicine embodiment of the present invention (x ± s, n=10)
Group number of animals dosage (g/kg) content of triglyceride (mmol/L)
Model control group 10 0.57 ± 0.28
Positive controls 10 0.32 0.23 ± 0.11
*
Experiment medicine group 10 3.00 0.23 ± 0.05
*
Illustrate: with the model matched group relatively:
*P＜0.01.
As seen from Table 4: Tibetan medicine embodiment 1 of the present invention, positive controls Bezoar pill for lowering blood pressure and model control group compare, and the equal highly significant of group difference (P＜0.01) illustrates that Tibetan medicine embodiment 1 of the present invention can significantly suppress the rising of rat blood serum content of triglyceride.
The influence of [test example 3] 1 pair of mice syngignoscism of Tibetan medicine embodiment of the present invention:
Test material: anthology invention Tibetan medicine embodiment 1; Bezoar pill for lowering blood pressure is produced by the Beijing Tongrentang Technology Development Co.ltd. Pharmaceutical Factory, lot number 20091013; Kunming mouse is provided by Qinghai Province's Experimental Animal Center.
Experimental technique: choose 60 kunming mices, male and female half and half, body weight 18～21g; be divided into 3 groups at random, establish model control group, positive controls (Bezoar pill for lowering blood pressure 0.32g/Kg) and experiment medicine group (Tibetan medicine embodiment 1 of the present invention, dosage 3.00g/kg); gastric infusion, 20ml/Kg.Behind the administration 60min, lumbar injection the eleventh of the twelve Earthly Branches barbital sodium (32mg/Kg) is observed and respectively to be organized mice upset areflexia and reach 1min and be sleeping index.
Experimental result: the influence of the sleeping number of 1 pair of mice of Tibetan medicine embodiment of the present invention sees Table 5.
The influence of the sleeping number of 1 pair of mice of table 5 Tibetan medicine embodiment of the present invention (x ± s, n=20)
The sleeping percentage rate (%) of the sleeping number of group number of animals dosage (g/kg)
Model control group 20 00
Positive controls 20 0.32 14 70
*
Experiment medicine group 20 3.00 16 80
*
Illustrate: with the model matched group relatively:
*P＜0.01.
As seen from Table 5: the sleeping rate of positive controls Bezoar pill for lowering blood pressure animal is 70%, and the sleeping rate of Tibetan medicine embodiment 1 animal of the present invention reaches 80%, compares with model control group, and credit is analysed by statistics, difference highly significant (P＜0.01).Illustrate that 1 pair of mice of Tibetan medicine embodiment of the present invention has tangible syngignoscism.Therefore, clinically calm and hypnosis there is certain value.
The clinical observation on the therapeutic effect of [test example 4] Tibetan medicine embodiment 1 treatment hypertension of the present invention:
Physical data: in JIUYUE, 2009～2011 a year JIUYUE is accepted hyperpietic's totally 120 examples for medical treatment, is divided into two groups at random by digital method, and 60 examples are organized in treatment, male 33 examples, women 27 examples; 45.1 years old mean age; 1 grade of hypertension 34 example, 2 grades of hypertension 20 examples, 3 grades of hypertension 6 examples.Matched group 60 examples, male 32 examples, women 28 examples; 44.5 years old mean age; 1 grade of hypertension 31 example, 2 grades of hypertension 21 examples, 3 grades of hypertension 8 examples.The age of two groups of cases, sex and physical data difference not statistically significant.
Diagnostic criteria: formulate about the related standards in " hypertension therapeutic guide " with reference to international hypertension alliance of World Health Organization (WHO) in 1999.1. 1 grade of hypertension: systolic pressure 140～159mmHg and (or) diastolic pressure 90～99mmHg; 2. 2 grades of hypertension: systolic pressure 160～179mmHg and (or) diastolic pressure 100～109mmHg; 3. 3 grades of hypertension: systolic pressure 〉=180mmHg and (or) diastolic pressure 〉=110mmHg.
Exclusion standard: the age is below 40 years old or more than 70 years old; Be associated with serious primary disease such as liver, kidney, hemopoietic system, psychotic; Intentionally, renal failure and retinal hemorrhage person; Secondary hypertensions such as Secondary cases hyperthyroidism, primary aldosteronism and renal hypertension; Systolic pressure 〉=180mmHg and/or diastolic pressure 〉=110mmHg person.
Therapeutic Method: 1, treatment group: adopt Tibetan medicine embodiment 1 of the present invention, 1.5g/ time, 1 day 3 times, warm water delivery service.
2, matched group: Bezoar pill for lowering blood pressure, 1.6g/ time, 1 day 1 time, warm water delivery service.
Two groups is 1 course for the treatment of to treat 30 days all, finishes the statistics therapeutic outcome 1 course for the treatment of.
Clinical efficacy evaluation criteria: efficacy of antihypertensive treatment evaluation criteria: with reference to " new Chinese medicine clinical research guideline ", 1. produce effects: diastolic pressure declines 〉=10mmHg, and be down to normally or be not down to normally, but decline 〉=20mmHg; 2. effective: diastolic pressure decline＜10mmHg, but be down to normal or the 10～19mmHg that descends; Or systolic pressure decline 〉=30mmHg; 3. invalid: blood pressure does not reach above-mentioned standard after treating.
Tcm syndrome scoring and curative effect determinate standard: clinical cardinal symptom is divided into primary symptom and time disease, all be divided into 4 grades by its light and heavy degree, cardinal symptoms such as dizziness and headache, agitation uncomfortable in chest, soreness of the waist and knees count 2 fens respectively, 4 minutes, 6 minutes, other symptoms such as flushing conjunctival congestion, dry mouth with bitter taste, palpitation and insomnia count 1 fen respectively, 2 minutes, 3 minutes, asymptomatic person counted 0 fen.The tcm syndrome curative effect determinate standard is formulated with reference to " the clinical research guideline of new Chinese medicine treatment hypertension ".Produce effects: clinical symptoms, sign are obviously improved, and the syndrome integration reduces 〉=70%; Effectively: clinical symptoms, sign all take a favorable turn, and the syndrome integration reduces 〉=30%; Invalid: clinical symptoms, sign do not have obvious improvement, even increase the weight of, the syndrome integration reduces less than 30%.
Produce effects adds and effectively adds up to total effective rate.
Clinical observation result sees Table 6,7,8,9.
The table 6 liang group blood pressure lowering amplitude of variation situation (mmHg of x ± s)
Group example number systolic pressure diastolic pressure pulse pressure
Treatment group treatment preceding 60 163.41 ± 16.32 101.51 ± 10.71 71.13 ± 11.38
Treatment back 60 132.68 ± 12.71
*83.53 ± 9.32
*58.17 ± 11.72
*
Treatment of control group preceding 60 157.97 ± 11.51 94.17 ± 10.12 69.67 ± 12.75
Treatment back 60 130.45 ± 11.68
*84.34 ± 7.49
*54.74 ± 9.88
*
Annotate: relatively preceding with the treatment of this group
*P＜0.05.
As seen from Table 6: self more all there is statistical significance (P＜0.05) two groups of systolic pressures, diastolic pressure treatment front and back, comparison not statistically significant between two groups (P〉0.05), the blood pressure lowering amplitude for the treatment of group systolic pressure, diastolic pressure all is higher than matched group, but not statistically significant (P〉0.05).
Table 7 liang group efficacy of antihypertensive treatment comparison (example, %)
Group example digital display is imitated the enabledisable total effective rate
Treatment organizes 60 45
*10 5 91.67
*
Matched group 60 33 18 9 85.00
Annotate: compare with matched group
*P＜0.05.
Table 8 liang group tcm syndrome curative effect comparison (example, %)
Group example digital display is imitated the enabledisable total effective rate
Treatment organizes 60 36 19 5 91.67
*
Matched group 60 28 14 18 70.00
Annotate: compare with matched group
*P＜0.01.
Treatment group tcm syndrome integration was reduced to 0.88 fen ± 0.12 minute (P＜0.01) in preceding 1.43 minutes ± 0.65 minute by treatment; Matched group by treatment reduced to 1.34 fens in preceding 1.42 minutes ± 0.52 minute ± 0.28 minute.Between the group for the treatment of back statistical significance (P＜0.01) is arranged relatively, the effect that the treatment group is improved the tcm syndrome integrated value obviously is better than matched group.
A blood lipids index (the mmol/L of x ± s) relatively before and after the treatment of table 9 liang group
Group example number TC TG HDL-C
Treatment group treatment preceding 60 7.37 ± 0.96 2.25 ± 0.77 0.87 ± 0.18
Treatment back 60 4.57 ± 1.05
* #1.48 ± 0.45
* #1.25 ± 0.27
* #
Treatment of control group preceding 60 7.28 ± 1.05 2.18 ± 0.86 0.78 ± 0.22
Treatment back 60 6.72 ± 1.12 2.03 ± 0.57 0.88 ± 0.26
Annotate: relatively preceding with the treatment of this group
*P＜0.05,
*P＜0.01; With comparison after the treatment of control group
#P＜0.05.
Treatment group treatment back TC, TG significantly reduces, and high density lipoprotein (HDL-C) obviously raises (P＜0.05 or P＜0.01), and the matched group curative effect is not remarkable, and statistical significance (P＜0.05) is relatively arranged between group.
Untoward reaction: have no adverse reaction in two groups of therapeutic processes; The check hepatic and renal function was all normal after finished two groups of courses for the treatment of.
Clinical observation result shows: after two groups of patients used above Drug therapy, blood pressure obviously descended, and clinical symptoms such as dizziness and headache, agitation uncomfortable in chest, soreness of the waist and knees obviously alleviate or disappear, and illustrate that Tibetan medicine embodiment 1 of the present invention has the good curing effect.Dizziness and headache, agitation uncomfortable in chest, soreness of the waist and knees etc. improve aspect, total effective rate and all are better than matched group, and Tibetan medicine embodiment 1 treatment hypertension determined curative effect of the present invention is described, are worth clinical expansion to use, and have certain application prospect.
Claims (8)
1. Tibetan medicine for the treatment of hypertension, it is characterized in that it is made up of active component or is made up of active component and acceptable accessories, wherein said active component is to be made by following concrete materials of weight proportions medicine: Lignum Aquilariae Resinatum 20～100g, Radix Pecteilis susannae 10～80g, Herba Corydalis 10～80g, Radix onosmatis 10～60g, Herba Lycopodii 10～60g, the Radix Aucklandiae 10～60g, Herba pleurospermi thomsonii 10～60g, DAJIANJU 10～80g, ZANGJINJIER 20～100g, Lacca 10～60g, ZANGQIANCAO 10～80g, Rhizoma Gastrodiae 10～60g, Fructus Choerospondiatis 10～60g, Fructus Phyllanthi 20～100g, Corydalisimpatiens(Pall.)Fisch 10～60g.
2. Tibetan medicine according to claim 1, wherein said active component is to be made by following concrete materials of weight proportions medicine: Lignum Aquilariae Resinatum 48g, Radix Pecteilis susannae 36g, Herba Corydalis 36g, Radix onosmatis 28g, Herba Lycopodii 28g, Radix Aucklandiae 28g, Herba pleurospermi thomsonii 28g, DAJIANJU 36g, ZANGJINJIER 42g, Lacca 28g, ZANGQIANCAO 36g, Rhizoma Gastrodiae 28g, Fructus Choerospondiatis 28g, Fructus Phyllanthi 42g, Corydalisimpatiens(Pall.)Fisch 28g.
3. Tibetan medicine according to claim 1 and 2, it is peroral dosage form.
4. Tibetan medicine according to claim 3, it is powder, pill, granule, capsule or tablet.
5. the preparation method of the described Tibetan medicine of claim 1, it comprises the following steps: to take by weighing following concrete materials of weight proportions medicine: Lignum Aquilariae Resinatum 20～100g, Radix Pecteilis susannae 10～80g, Herba Corydalis 10～80g, Radix onosmatis 10～60g, Herba Lycopodii 10～60g, the Radix Aucklandiae 10～60g, Herba pleurospermi thomsonii 10～60g, DAJIANJU 10～80g, ZANGJINJIER 20～100g, Lacca 10～60g, ZANGQIANCAO 10～80g, Rhizoma Gastrodiae 10～60g, Fructus Choerospondiatis 10～60g, Fructus Phyllanthi 20～100g, Corydalisimpatiens(Pall.)Fisch 10～60g; Mix, be ground into fine powder then jointly, mixing is made active component.
6. the preparation method of the described Tibetan medicine of claim 1, it comprises the following steps: to take by weighing following concrete materials of weight proportions medicine: Lignum Aquilariae Resinatum 20～100g, Radix Pecteilis susannae 10～80g, Herba Corydalis 10～80g, Radix onosmatis 10～60g, Herba Lycopodii 10～60g, the Radix Aucklandiae 10～60g, Herba pleurospermi thomsonii 10～60g, DAJIANJU 10～80g, ZANGJINJIER 20～100g, Lacca 10～60g, ZANGQIANCAO 10～80g, Rhizoma Gastrodiae 10～60g, Fructus Choerospondiatis 10～60g, Fructus Phyllanthi 20～100g, Corydalisimpatiens(Pall.)Fisch 10～60g; Mix, adopt decoction and alcohol sedimentation technique or ethanol extract from water precipitation to make active component.
7. according to claim 5 or 6 described preparation methoies, wherein take by weighing following concrete materials of weight proportions medicine: Lignum Aquilariae Resinatum 48g, Radix Pecteilis susannae 36g, Herba Corydalis 36g, Radix onosmatis 28g, Herba Lycopodii 28g, Radix Aucklandiae 28g, Herba pleurospermi thomsonii 28g, DAJIANJU 36g, ZANGJINJIER 42g, Lacca 28g, ZANGQIANCAO 36g, Rhizoma Gastrodiae 28g, Fructus Choerospondiatis 28g, Fructus Phyllanthi 42g, Corydalisimpatiens(Pall.)Fisch 28g.
8. according to claim 5 or 6 described preparation methoies, it also comprises the following steps: active component and acceptable accessories are made powder, pill, granule, capsule or tablet.
9. according to the described preparation method of claim 7, it also comprises the following steps: active component and acceptable accessories are made powder, pill, granule, capsule or tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102193404A CN102716347B (en) | 2012-06-29 | 2012-06-29 | Tibetan medicine for treating hypertension and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102193404A CN102716347B (en) | 2012-06-29 | 2012-06-29 | Tibetan medicine for treating hypertension and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102716347A CN102716347A (en) | 2012-10-10 |
| CN102716347B true CN102716347B (en) | 2013-08-14 |
Family
ID=46942301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012102193404A Active CN102716347B (en) | 2012-06-29 | 2012-06-29 | Tibetan medicine for treating hypertension and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102716347B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103330858B (en) * | 2013-07-10 | 2014-07-30 | 宋永心 | Tibetan medicine used for treating cerebral thrombus and preparation method thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1140279C (en) * | 2001-01-21 | 2004-03-03 | 白玛加措 | Blood-cleaning pill |
| CN1129447C (en) * | 2001-01-21 | 2003-12-03 | 白玛加措 | Anshen pill-treating cardio-cerebral angiopathy |
| WO2005082391A1 (en) * | 2004-03-01 | 2005-09-09 | Kaneka Corporation | AGONIST TO HUMAN β3 ADRENALINE RECEPTOR |
| CN100389816C (en) * | 2005-07-06 | 2008-05-28 | 甘肃奇正藏药有限公司 | Tibetan medicine formulation for treating hyperlipemia, and its preparing method |
| KR100577674B1 (en) * | 2006-02-03 | 2006-05-10 | 신흥묵 | A curing and preventing pharmaceutical composition having an effect of anti-hypertension inducing by containing a extract of chinese herb |
| CN1857329A (en) * | 2006-03-02 | 2006-11-08 | 甘肃奇正藏药有限公司 | Preparing method of Chinese medicine composition with starch |
| JP2010202634A (en) * | 2008-06-05 | 2010-09-16 | Green Kanpo Seiyaku Kk | Crude drug-containing composition and use thereof |
| CN101543554A (en) * | 2008-12-30 | 2009-09-30 | 萨仁格日乐 | Anaesthetic for curing hyperlipoidemia |
| RU2437674C1 (en) * | 2010-06-18 | 2011-12-27 | Институт общей и экспериментальной биологии Сибирского отделения Российской Академии наук (ИОЭБ СО РАН) | Method of obtaining medication, possessing adaptogenic activity |
| CN102441156B (en) * | 2011-12-14 | 2013-06-12 | 多吉 | Traditional Tibetan medicinal composition and preparation method thereof |
-
2012
- 2012-06-29 CN CN2012102193404A patent/CN102716347B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102716347A (en) | 2012-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102743737B (en) | Chinese medicinal preparation for effectively treating tracheitis | |
| CN103520572B (en) | A kind of Chinese medicine composition being used for the treatment of atopic dermatitis and preparation method thereof | |
| CN101716242B (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases | |
| CN104689226A (en) | Traditional Chinese medicine composition for treating children with rheumatoid arthritis and preparation method thereof | |
| CN103599403B (en) | Traditional Chinese medicine composition for treating migraine and preparation method thereof | |
| CN102988733A (en) | Traditional Chinese medicine composition for treating postpartum hypogalactia and preparation method thereof | |
| CN104383257A (en) | Chinese medicinal preparation for treating xerophthalmia due to liver depression and deficiency of yin | |
| CN103055066A (en) | Traditional Chinese medicine for improving sleep and preparation method thereof | |
| CN105687788A (en) | Pharmaceutical composition capable of softening blood vessels and application thereof | |
| CN102716347B (en) | Tibetan medicine for treating hypertension and preparation method thereof | |
| CN104906430A (en) | Traditional Chinese medicine preparation for treating xerophthalmia and preparation method thereof | |
| CN103860773A (en) | Traditional Chinese medicine composition for treating myocardial ischemia and preparation method thereof | |
| CN103341095B (en) | Clysis liquid used for chronic renal failure | |
| CN102416121A (en) | Application of medicinal composition to preparation of medicaments for treating gastric ulcer | |
| CN102240352A (en) | Narcotic powder for tooth extraction and preparation method thereof | |
| CN105106710A (en) | Preparing method of lung-moistening and phlegm-removing preparation for treating asthma | |
| CN105833043A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating primary hypertension | |
| CN104888178A (en) | Infantile diarrhea treatment traditional Chinese medicine | |
| CN104758733A (en) | External lotion for treating senile vaginitis | |
| CN103330896B (en) | Preparation method of powder for treating postpartum nonspecific vaginitis | |
| CN102416120A (en) | Application of medicinal composition to preparation of medicament for treating erosive gastritis | |
| CN102430073A (en) | Medicinal composition for treating peptic ulcer | |
| CN1973871B (en) | Largngopharyngitis treating medicine composition and its preparation | |
| CN105770081A (en) | Composition preparation used for promoting healing after cerebral hemorrhage operation and preparation method thereof | |
| CN104189870A (en) | Traditional Chinese medicine for treating allergic asthma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Jiumei Pengcuo Inventor before: Song Yongxin |
|
| COR | Change of bibliographic data | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20161025 Address after: 810000 Xining biological science and Technology Industrial Park, No. three, No. 18, Qinghai Patentee after: Qinghai Jiumei Zang Drug Drug Co.,Ltd. Address before: 810008 Qinghai province Xining City West District Xishan Lane 20 building No. 1 room 341 Patentee before: Song Yongxin |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Tibetan medicine for treating hypertension and preparation method thereof Effective date of registration: 20200525 Granted publication date: 20130814 Pledgee: Qinghai Chuangqi Finance Leasing Co.,Ltd. Pledgor: Qinghai Jiumei Zang Drug Drug Co.,Ltd. Registration number: Y2020630000001 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210517 Granted publication date: 20130814 Pledgee: Qinghai Chuangqi Finance Leasing Co.,Ltd. Pledgor: Qinghai Jiumei Zang Drug Drug Co.,Ltd. Registration number: Y2020630000001 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A Tibetan medicine for treating hypertension and its preparation method Effective date of registration: 20210602 Granted publication date: 20130814 Pledgee: Qinghai Chuangqi Finance Leasing Co.,Ltd. Pledgor: Qinghai Jiumei Zang Drug Drug Co.,Ltd. Registration number: Y2021630000003 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230608 Granted publication date: 20130814 Pledgee: Qinghai Chuangqi Finance Leasing Co.,Ltd. Pledgor: Jiumei Pengcuo|Qinghai Jiumei Zang Drug Drug Co.,Ltd. Registration number: Y2021630000003 |